FIA
GENB

FNY Investment Advisers’s Generate Biomedicines GENB Stock Holding History

FNY Investment Advisers’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,000
Closed -$37K – 1132
2026
Q1 		$37K Buy
+3,000
New +$36.6K 0.02% 406

Other funds holding GENB

AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

FNY Investment Advisers's GENB Position: Q2 2026 in Review

FNY Investment Advisers sold out of Generate Biomedicines (GENB) in Q2 2026, closing a stake of 3,000 shares — an estimated $37K sold.

FNY Investment Advisers first reported a position in GENB in Q1 2026 and held it in 1 quarter. The position peaked at $37K in Q1 2026. 12 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • FNY Investment Advisers reported no remaining Generate Biomedicines position as of Q2 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 3,000 Generate Biomedicines shares in Q2 2026, an estimated $37K.
  • FNY Investment Advisers first reported a position in Generate Biomedicines in Q1 2026 and held it in 1 quarter.
  • FNY Investment Advisers's Generate Biomedicines position peaked at $37K in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.